ImmunityBio gets FDA authorisation to begin trial of novel Covid-19 vaccine candidate

This article was originally published here

The human adenovirus (hAd5) vector vaccine candidate has been designed to target both the inner nucleocapsid (N) and outer spike (S) proteins, said ImmunityBio. The N-protein has been

The post ImmunityBio gets FDA authorisation to begin trial of novel Covid-19 vaccine candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply